GlassScriptPhysician profile
Amritha Parthasarathy
NPI 1174010771
$10,235.82
in general payments reported to CMS, 2019-2025
46 companies · $5,410 in 2025
The $5,410 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.09 · 2020: $206 · 2023: $1,544 · 2024: $3,054 · 2025: $5,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,995 · Education: $12.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,995.41 |
| Education | $12.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $749.71 | 2023-2025 | Vyepti, Rexulti |
| Abbvie INC. | $704.87 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $689.92 | 2023-2025 | Ultomiris, Soliris |
| Sk Life Science, INC. | $689.56 | 2023-2025 | Xcopri |
| Neurelis, INC. | $682.46 | 2023-2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $680.70 | 2023-2025 | Fycompa |
| Biogen, INC. | $644.74 | 2023-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $611.72 | 2023-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $588.15 | 2024-2025 | |
| Lilly USA, LLC | $357.70 | 2023-2025 | Kisunla, Amyvid |
| Genentech USA, INC. | $356.41 | 2020-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Eisai INC. | $343.28 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $314.39 | 2023-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $288.05 | 2023-2025 | Rexulti, Nuedexta |
| Ani Pharmaceuticals, INC. | $242.29 | 2025 | Purified Cortrophin Gel |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $210.90 | 2023-2025 | Mavenclad |
| Csl Behring | $198.53 | 2025 | Hizentra |
| Merz Pharmaceuticals, LLC | $182.50 | 2024-2025 | Xeomin, Inbrija |
| Sumitomo Pharma America, INC. | $132.13 | 2023-2024 | Aptiom |
| Celgene Corporation | $124.54 | 2023-2025 | Zeposia |
| Janssen Biotech, INC. | $120.04 | 2025 | |
| Acorda Therapeutics, INC | $115.79 | 2023-2024 | Inbrija, Ampyra |
| Harmony Biosciences LLC | $105.14 | 2023-2025 | Wakix |
| Octapharma USA, INC. | $95.80 | 2023-2025 | Panzyga |
| Argenx US, INC. | $89.10 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $74.40 | 2025 | |
| Pfizer INC. | $65.30 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $63.71 | 2024-2025 | Wainua |
| Teva Pharmaceuticals USA, INC. | $63.19 | 2025 | Austedo Xr |
| Amgen INC. | $60.46 | 2025 | |
| Jazz Pharmaceuticals INC. | $58.88 | 2025 | |
| Mallinckrodt Hospital Products INC. | $58.63 | 2023 | Acthar |
| Vanda Pharmaceuticals INC. | $57.52 | 2025 | Ponvory |
| Genzyme Corporation | $50.80 | 2025 | |
| Kyowa Kirin, INC. | $48.54 | 2024 | Nourianz |
| Banner Life Sciences, LLC | $47.34 | 2024 | |
| Amneal Pharmaceuticals LLC | $42.20 | 2025 | Rytary |
| Biohaven Pharmaceuticals, INC. | $40.35 | 2020 | |
| Grifols USA, LLC | $37.71 | 2019-2020 | |
| Ge Healthcare | $33.65 | 2025 | |
| Axsome Therapeutics, INC. | $25.09 | 2025 | Symbravo |
| Xeris Pharmaceuticals, INC. | $21.60 | 2025 | Keveyis |
| Tanabe Pharma America, INC. | $18.26 | 2025 | |
| Boston Scientific Corporation | $17.32 | 2024 | Watchman Flx |
| Acadia Pharmaceuticals INC | $16.25 | 2023 | Nuplazid |
| Scilex Pharmaceuticals INC. | $16.20 | 2023 | Elyxyb |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amritha Parthasarathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.